^
Association details:
| Biomarker: | PTCH E947T |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Erivedge (vismodegib) (Hedgehog cell-signalling pathway inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.
Published date:
05/26/2022
Excerpt:
2 PRs were seen in pts with a skin/soft tissue sarcoma (PTCH) and a meningioma (SMO) with a median duration of response 14 months. The 6-month PFS rate was similar in MATCH-confirmed and analyzable pts (22.4% and 23.2% respectively) and median PFS was identical at 1.8 months....vismodegib was well-tolerated with mostly grade 1-2 toxicities and substantial responses were seen in patients with SMOPro641Ala and PTCHGlu947Ter alterations.
DOI:
10.1200/JCO.2022.40.16_suppl.3010
Trial ID:
